Narasin + Nicarbazin

Verify with FDA CVM →

160 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
160
Total Reports
109
Deaths Reported
6810.0%
Death Rate

Active Ingredients

NarasinNicarbazin

Administration Routes

OralUnknownRespiratory (Inhalation)Ophthalmic

Species Affected

Chicken 156
Human 2
Unknown 1
Dog 1

Most Affected Breeds

Chicken (unknown) 121
Chicken (other) 28
Chicken (unspecified) 4
Unknown 3
Cornish Cobb 1
Crossbred Chicken 1
Dog (unknown) 1
Mixed (Chicken) 1

Most Reported Reactions

Death 68
Lack of efficacy (protozoa) - Coccidia 53
Increased mortality rate 40
Lack of efficacy - NOS 17
NT - Abnormal necropsy finding NOS 15
Enteritis 14
Loss of egg quantity 14
Digestive tract disorder NOS 12
Loss of egg quality 11
Abnormal necropsy finding 9
Death by euthanasia 8
Dermatitis 7

Outcome Breakdown

Died
104 (51.7%)
Outcome Unknown
66 (32.8%)
Euthanized
14 (7.0%)
Recovered/Normal
12 (6.0%)
Recovered with Sequela
4 (2.0%)
Ongoing
1 (0.5%)

Data Summary

Metric Value
Total adverse event reports 160
Reports involving death 109
Case-fatality rate (reported events) 6810.0%
Distinct species in reports 4
Distinct breeds in reports 8
Distinct reactions reported 20
Active ingredients on file 2

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Narasin + Nicarbazin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 160 adverse event reports referencing Narasin + Nicarbazin, including 109 reports in which the animal died — a 6810.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Narasin, Nicarbazin. Reported administration routes include Oral, Unknown, Respiratory (Inhalation), Ophthalmic. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Narasin + Nicarbazin reports are Chicken (156 reports), Human (2 reports), Unknown (1 reports), with Chicken accounting for the largest share. Within those species, Chicken (unknown) (121), Chicken (other) (28), Chicken (unspecified) (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Narasin + Nicarbazin are Death (68), Lack of efficacy (protozoa) - Coccidia (53), Increased mortality rate (40), Lack of efficacy - NOS (17). Of the 201 reports with a coded outcome, Died is the leading category at 51.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Narasin + Nicarbazin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial